Pediatrix Q2 net revenue $500.6M (+3% YoY); GAAP EPS $0.34, adjusted $0.39; EBITDA $59M

Pediatrix Medical Group, Inc.

2023-Q2 EPS reported $0.52 revenue$991,585,000

GAAP EPS from continuing ops $0.34 vs $0.36; adjusted EPS $0.39 vs $0.47 in prior year.
Adjusted EBITDA $59.1M vs $65.6M YoY; 2023 EBITDA guidance reaffirmed at $235-245M.
Same-unit revenue up 3.2% (reimbursement +2.6%, volume +0.6%); no CARES Act funds in Q2.
Cash from ops $92.6M (+$11M YoY); capex $8.1M; total debt $675M.
Weighted average shares fell to 82.7M from 85.6M due to share repurchases.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Pediatrix Medical Group, Inc. reported six months ended June 30, 2023 results: revenue $991.6 million, net income $42.5 million, EPS $0.52 per share.

Period: six months ended June 30, 2023
Revenue: $991.6 million
Net income: $42.5 million
EPS: $0.52 per share
Result: preliminary results

Exact text from the filing

Operating Results from Continuing Operations – Six Months Ended June 30, 2023 For the six months ended June 30, 2023, Pediatrix generated revenue from continuing operations of $991.6 million, compared to $968.3 million for the prior-year period. Adjusted EBITDA from continuing operations for the six months ended June 30, 2023 was $99.2 million, compared to $116.2

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Pediatrix Medical Group, Inc. reported three months ended June 30, 2023 results: revenue $500.6 million, net income $28.3 million, EPS $0.34 per diluted share.

Period: three months ended June 30, 2023
Revenue: $500.6 million
Net income: $28.3 million
EPS: $0.34 per diluted share
Result: preliminary results

Exact text from the filing

reported Adjusted EPS from continuing operations of $0.39. For the 2023 second quarter, Pediatrix reported the following results from continuing operations: • Net revenue of $501 million; • Income from continuing operations of $28 million; and • Adjusted EBITDA of $59 million. “Our second quarter operating results were in line with our expectations and reflect

View on SEC.gov

Browse all earnings releases →

Pediatrix Medical Group, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-037559

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.